Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

82.77 +0.84 (+1.03%)
Streaming Delayed Price Updated: 10:22 AM EST, Jan 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ionis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
News headline image
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Ionis Pharma Extends Breakout; Biotech Restates Guide Despite Quarterly Miss ↗
The guidance stayed intact despite a wide second-quarter flop. 
Via Investor's Business Daily
News headline image
Ionis Pharmaceuticals: Q2 Earnings Insights ↗
  Ionis Pharmaceuticals (NASDAQ:IONS) reported its Q2 earnings results on Tuesday, August 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Moderna, PayPal And Some Other Big Gainers From Wednesday ↗
U.S. stocks closed higher on Wednesday, with the Dow Jones gaining more than 400 points. Here is the list of some big stocks moving higher in the previous session. 
Via Benzinga
News headline image
Where Ionis Pharmaceuticals Stands With Analysts ↗
Ionis Pharmaceuticals (NASDAQ:IONS) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
Recap: Ionis Pharmaceuticals Q1 Earnings ↗
Ionis Pharmaceuticals (NASDAQ:IONS) reported its Q1 earnings results on Wednesday, May 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
This Biotechnology Stock Jumped Over 360%; Here Are 106 Biggest Movers From Yesterday ↗
Gainers Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) shares surged 360.5% to settle at $19.80 on Wednesday on above-average volume. 
Via Benzinga
News headline image
Why Poseida Therapeutics Is Trading Higher By Around 100%, Here Are 75 Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Helius Medical Technologies, Inc. (NASDAQ: HSDT) shares jumped 167% to $1.72 after dropping 13% on Tuesday. 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗
Good morning, trader! It's time to start off Friday with a breakdown of the biggest pre-market stock movers traders need to know about! 
Via InvestorPlace
News headline image
Recap Of Thursday's Biotech Catalysts - End of The Day Summary ↗
 
Via Benzinga
News headline image
Ionis Reveals Positive Results From Anti-Blood Clot Therapy In Hemodialysis ↗
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced positive topline results of the Phase 2b clinical trial of fesomersen in patients with end-stage renal disease (ESRD) on hemodialysis. 
Via Benzinga
News headline image
FDA Accepts Biogen's Submission For Neurodegenerative Disease Drug Under Priority Review ↗
The U.S. Food and Drug Administration (FDA) has accepted Biogen’s (NASDAQ: BIIB) New Drug Application (NDA) for its lead asset Tofersen for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis... 
Via Benzinga
News headline image
Daily Biotech Pulse: EU Approval For AbbVie's Ulcerative Colitis Treatment, Angion Biomedica Evaluates Alternatives, Clinical Hold For Immuron's Bacterial Infection Candidate ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
7 Undervalued Biotech Stocks to Buy Before They Boom ↗
Despite recession fears, biological sciences will never go out of style, thus benefitting these undervalued biotech stocks to buy. 
Via InvestorPlace
News headline image
Recap of Wednesday's Biotech Catalysts - End of The Day Summary ↗
  
Via Benzinga
News headline image
The Daily Biotech Pulse: Europe Approves Second Round Of Booster Doses of mRNA COVID-19 Vaccines, Perrigo Seeks Approval For First OTC Birth Control Pill, MacroGenics Closes Head & Cancer Study After Patient Death ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
7 Best Biotech Stocks to Buy in July 2022 ↗
The best biotech stocks to buy are a lot like the best computer stocks 40 years ago; the biggest similarity is how hard they are to predict. 
Via InvestorPlace
News headline image
Cathie Wood's Ark Invest Sheds $35M In 3D Printing Company Stratasys — What It Bought Instead ↗
As the market reopened following the long July 4 weekend, Cathie Wood-run Ark Invest made some portfolio moves, notable among which is the offloading of a huge chunk of Stratasys Ltd. (NASDAQ: SSYS)... 
Via Benzinga
News headline image
EXCLUSIVE: Has Biotech Bottomed? NYSE Executive Floor Director Says Biogen And These 3 Stocks Look Poised To Outperform ↗
Markets continue to trend lower amid rising inflation and Fed uncertainty, but one New York Stock Exchange floor director says the bottom may be in for a couple of beaten-down sectors. 
Via Benzinga
News headline image
Recap of Tuesday's Biotech Catalysts - End of the Day Summary ↗
Ionis (NASDAQ: IONS) announced that Eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid... 
Via Benzinga
Revenues From Treatment of Rare Neurological Disorders Worldwide Are Poised to Surpass $12 Billion in 2026
Palm Beach, FL – June 22, 2022 – FinancialNewsMedia.com News Commentary Neuroinflammatory disorder is the study of conditions where immune responses which damage components of the nervous system. It... 
Via FinancialNewsMedia
News headline image
The Daily Biotech Pulse: Thumbs Down For Acadia's Pimavanserin, Pfizer Buys Stake In Valneva, AstraZeneca - Ionis Eplontersen Aces Rare Disease Trial ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
AstraZeneca - Ionis Eplontersen Achieves Positive Data In Rare Disease Trial ↗
 
Via Benzinga
News headline image
5 Cathie Wood Stocks to Buy in June ↗
These are the five best Cathie Wood stocks to buy in June. EXAS, IONS, KTOS, TRMB, and PATH can make excellent investments. 
Via InvestorPlace
News headline image
Cathie Wood Is Selling Gene Editing Stocks. Here’s Why. ↗
Cathie Wood has recently sold off large positions in several gene-editing stocks from her ARKG ETF. What's behind Wood's latest moves? 
Via InvestorPlace
News headline image
Ionis Pharmaceuticals Earnings Perspective: Return On Capital Employed ↗
Benzinga Pro data, Ionis Pharmaceuticals (NASDAQ:IONS) reported Q1 sales of $142.00 million. Earnings fell to a loss of $65.17 million, resulting in a 129.01% decrease from last quarter. 
Via Benzinga
News headline image
What 5 Analyst Ratings Have To Say About Ionis Pharmaceuticals ↗
Within the last quarter, Ionis Pharmaceuticals (NASDAQ:IONS) has observed the following analyst ratings: 
Via Benzinga
News headline image
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
How To Attend Ionis Pharmaceuticals Q1 2022 Earnings Conference Call ↗
Ionis Pharmaceuticals (NASDAQ:IONS) will host a conference call at 11:30 AM ET on May 4, 2022, to discuss Q1 2022 earnings results. 
Via Benzinga
News headline image
7 Potential Biotech Stocks Buyout Targets in 2022 ↗
Drug development is a cumbersome process and M&A is a win-win proposition for both the acquirer and the target company. 
Via InvestorPlace
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.